Overview
Introduction
With millions of diabetes patients suffering from neuropathic pain worldwide and no treatments yet approved for this indication in the US, the diabetic neuropathic pain (DNP) market is set for some dramatic changes. Nevertheless, the launch of novel disease modifying therapies and the flood of generic gabapentin products are but two of the challenges facing potential investors
Scope
- Quantitative treatment data from over 364 physicians from the US, Japan, France, Germany, Italy, Spain and the UK
- Analysis of epidemiology, assessment and referral patterns, first- to third-line treatments, and unmet market needs
- Discussion of the R&D drug pipeline for DNP, including analysis of ruboxistaurin, fidarestat, pregabalin, lamotrigine, and duloxetine
- Coverage of the hot topics including the upcoming launch of pregabalin and disease modifying therapies
Report Highlights
DNP patients are often referred to neurologists or pain specialists for treatment, where they are likely given gabapentin and/or amitriptyline. However, as these treatments often only provide marginal relief of DNP symptoms, there remains a need for improved long-term pain management
With the launch of pregabalin in 2004, Pfizer will effectively retain much of its market share when gabapentin finally loses US patent protection. Approval for DNP in the US will be a major advantage in the increasingly competitive neuropathic pain market as currently there are no drugs licensed for this indication
Over the coming years competition in the market will be fierce; therefore smaller companies will need to establish clear positioning versus major players, requiring significant investment. Such smaller companies should consider alternative strategies to head-to-head DNP monotherapy competition
Reasons to Purchase
- Forecast product sales by understanding key aspects of DNP epidemiology, diagnosis, and treatment
- Gain a better understanding of the challenges faced by future players in the DNP market
- Predict trends in the treatment of DNP and how to capitalize on forthcoming changes in treatment practice
| 
View Cart
